Neuroprotection: Lessons from a Spectrum of Neurological Disorders

Abstract

Get full access to this article

View all access options for this article.

References

Singhal

Dalkara

. Advances in stroke neuroprotection: hyperoxia and beyond. Neuroimaging Clin North Am 2005; 15:697–720.

Marler

: NINDS-sponsored clinical trials in stroke: past, present, and future. Stroke 2002; 33:311–2.

Kidwell

Liebeskind

Starkman

. Trends in acute ischemic stroke trials through the 20th century. Stroke 2001; 32:1349–59.

Rinkel

Feigin

Algra

. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2005 CD000277.

The National Institute of Neurological Disorders and Stroke rt-PA stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581–87.

Furlan

Higashida

Wechsler

. Intraarterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 1999; 282:2003–11.

Hacke

Albers

Al-Rawi

. The desmoteplase in acute ischemic stroke trial (DIAS). A phase II mri-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36:66–73.

Mayer

Brun

Begtrup

. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352:777–85.

Beal

: Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 2000; 23:298–304.

10.

Schapira

Olanow

: Neuroprotection in parkinson disease: mysteries, myths, and misconceptions. JAMA 2004; 291:358–64.

11.

Zhang

Narayanan

Friedlander

: Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 2003; 53:267–70.

12.

Klivenyi

Kiaei

Gardian

. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 2004; 88:576–82.

13.

Holloway

Dick

: Clinical trial end points: on the road to nowhere? Neurology 2002; 58:679–86.

14.

Parkinson Study Group: Effect of deprenyl on the progression of disability in early parkinson's disease. The Parkinson Study Group. N Engl J Med 1989; 321:1364–71.

15.

Bakshi

Hutton

Miller

. The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis. Neurology 2004; 63:S3–11.

16.

The NINDS NET-PD Investigators: A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson's disease. Neurology 2006; 66:664–71.

17.

Fisher

Albers

Donnan

. Enhancing the development and approval of acute stroke therapies: stroke therapy academic industry roundtable. Stroke 2005; 36:1808–13.

18.

Piriyawat

Labiche

Burgin

. Pilot dose-escalation study of caffeine plus ethanol (caffeinol) in acute ischemic stroke. Stroke 2003; 34:1242–5.

19.

Broderick

Moskowitz

: t-PA and proteolysis in the neurovascular unit. Stroke 2004; 35:354–6.

20.

Singhal

Benner

Roccatagliata

. A pilot study of normobaric oxygen therapy in acute ischemic stroke. Stroke 2005; 36:797–802.

21.

Alexandrov

Molina

Grotta

. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004; 351:2170–8.

22.

The Hypothermia after Cardiac Arrest Study Group: Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002; 346:549–56.

23.

Tilley

Marler

Geller

. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA stroke trial. Stroke 1996; 27:2136–42.